Compumedics Limited (ASX:CMP) Reports Record H1 FY25 Sales
Record Sales Orders
Compumedics Limited (ASX: CMP) reported record sales orders of $32.8 million for H1 FY25, a remarkable 55% increase compared to the same period last year, excluding MEG products. The growth was significantly driven by sales in the USA, which surged by 208% year-on-year, underscoring the demand for their sleep and Neuroscan businesses.
Regional Sales Performance
Sales from Asia also saw an increase, up 115% year-on-year. Europe contributed with a 10% growth in sales orders compared to H1 FY24. Notably, the Somfit device achieved sales orders of approximately $1.9 million, marking a 70% increase from the previous year, including a significant order from a global CPAP company.
Future Growth Outlook
The company anticipates FY25 sales to surpass $55 million, excluding MEG products, and projects EBITDA exceeding $5 million. Due to marketing and development expenses incurred during the first half, EBITDA is expected to be weighted toward the second half of FY25. The company will review its FY25 guidance following the release of its Appendix 4D around 24 February 2025.
CEO Comments
Dr. David Burton, Executive Chairman and CEO of Compumedics, stated that the sales momentum in the USA is expected to grow as new sales resources are deployed. He noted, “We are well placed to accelerate growth over H2 FY25 as we build relationships with large Independent Diagnostic Testing Facilities in the USA.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.